Recently, authors demonstrated that the use of the novel SGLT2 inhibitor, NGI001 in high fat diet-induced mice instigates suppression of lipid accumulation, inflammation, upregulation of β-oxidation, and they suggest that this inhibitor may be as a new therapeutic approach that can delay the onset of NAFLD [198]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.